{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T04:53:47Z","timestamp":1784091227615,"version":"3.55.0"},"reference-count":51,"publisher":"American Association for Cancer Research (AACR)","issue":"16","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2011,8,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Mutations of the von Hippel-Lindau (VHL) gene are frequent in clear cell renal cell carcinomas (ccRCC). Nonsense and frameshift mutations abrogate the function of the VHL protein (pVHL), whereas missense mutations can have different effects. To identify those missense mutations with functional consequences, we sequenced VHL in 256 sporadic ccRCC and identified 187 different VHL mutations of which 65 were missense mutations. Location and destabilizing effects of VHL missense mutations were determined in silico. The majority of the thermodynamically destabilizing missense mutations were located in exon 1 in the core of pVHL, whereas protein surface mutations in exon 3 affected the interaction domains of elongin B and C. Their impact on pVHL's functionality was further investigated in vitro by stably reintroducing VHL missense mutations into a VHL null cell line and by monitoring the green fluorescent protein (GFP) signals after the transfection of a hypoxia inducible factor (HIF)\u03b1-GFP expression vector. pVHL's functionality ranged from no effect to complete HIF stabilization. Interestingly, Asn78Ser, Asp121Tyr, and Val130Phe selectively influenced HIF1\u03b1 and HIF2\u03b1 degradation. In summary, we obtained three different groups of missense mutations: one with severe destabilization of pVHL; a second without destabilizing effects on pVHL but relevance for the interaction with HIF\u03b1, elongin B, and elongin C; and a third with pVHL functions comparable with wild type. We therefore conclude that the specific impact of missense mutations may help to distinguish between driver and passenger mutations and may explain responses of ccRCC patients to HIF-targeted therapies. Cancer Res; 71(16); 5500\u201311. \u00a92011 AACR.<\/jats:p>","DOI":"10.1158\/0008-5472.can-11-0757","type":"journal-article","created":{"date-parts":[[2011,6,29]],"date-time":"2011-06-29T22:22:02Z","timestamp":1309386122000},"page":"5500-5511","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":95,"title":["<i>VHL<\/i>\n                    Gene Mutations and Their Effects on Hypoxia Inducible Factor HIF\u03b1: Identification of Potential Driver and Passenger Mutations"],"prefix":"10.1158","volume":"71","author":[{"given":"Markus P.","family":"Rechsteiner","sequence":"first","affiliation":[{"name":"Authors' Affiliations:\u20081Institute of Surgical Pathology; and 2Clinics of Urology, University Hospital Zurich, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"von Teichman","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Institute of Surgical Pathology; and 2Clinics of Urology, University Hospital Zurich, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Nowicka","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Institute of Surgical Pathology; and 2Clinics of Urology, University Hospital Zurich, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tullio","family":"Sulser","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Institute of Surgical Pathology; and 2Clinics of Urology, University Hospital Zurich, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Schraml","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Institute of Surgical Pathology; and 2Clinics of Urology, University Hospital Zurich, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holger","family":"Moch","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Institute of Surgical Pathology; and 2Clinics of Urology, University Hospital Zurich, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2011,8,11]]},"reference":[{"key":"2022061702562644000_bib1","article-title":"Cancer Mondial. International Agency for Research on Cancer, World Health Organization, Lyon, France"},{"key":"2022061702562644000_bib2","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1158\/0008-5472.CAN-05-3074","article-title":"Genetic and epigenetic analysis of von Hippel-Lindau (VHL) gene alterations and relationship with clinical variables in sporadic renal cancer","volume":"66","author":"Banks","year":"2006","journal-title":"Cancer Res"},{"key":"2022061702562644000_bib3","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/35017054","article-title":"Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein","volume":"2","author":"Ohh","year":"2000","journal-title":"Nat Cell Biol"},{"key":"2022061702562644000_bib4","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/20459","article-title":"The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis","volume":"399","author":"Maxwell","year":"1999","journal-title":"Nature"},{"key":"2022061702562644000_bib5","doi-asserted-by":"crossref","first-page":"9361","DOI":"10.1128\/MCB.23.24.9361-9374.2003","article-title":"Differential roles of hypoxia-inducible factor 1alpha (HIF-1alpha) and HIF-2alpha in hypoxic gene regulation","volume":"23","author":"Hu","year":"2003","journal-title":"Mol Cell Biol"},{"key":"2022061702562644000_bib6","doi-asserted-by":"crossref","first-page":"5675","DOI":"10.1128\/MCB.25.13.5675-5686.2005","article-title":"Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma","volume":"25","author":"Raval","year":"2005","journal-title":"Mol Cell Biol"},{"key":"2022061702562644000_bib7","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.gde.2006.12.006","article-title":"Hypoxia-inducible factors: central regulators of the tumor phenotype","volume":"17","author":"Gordan","year":"2007","journal-title":"Curr Opin Genet Dev"},{"key":"2022061702562644000_bib8","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1158\/1541-7786.89.2.2","article-title":"Inhibition of hypoxia-inducible factor is sufficient for growth suppression of VHL\u2212\/\u2212 tumors","volume":"2","author":"Zimmer","year":"2004","journal-title":"Mol Cancer Res"},{"key":"2022061702562644000_bib9","doi-asserted-by":"crossref","first-page":"E83","DOI":"10.1371\/journal.pbio.0000083","article-title":"Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth","volume":"1","author":"Kondo","year":"2003","journal-title":"PLoS Biol"},{"key":"2022061702562644000_bib10","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.ccr.2008.10.016","article-title":"HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma","volume":"14","author":"Gordan","year":"2008","journal-title":"Cancer Cell"},{"key":"2022061702562644000_bib11","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.ccr.2007.02.006","article-title":"HIF-2alpha promotes hypoxic cell proliferation by enhancing c-myc transcriptional activity","volume":"11","author":"Gordan","year":"2007","journal-title":"Cancer Cell"},{"key":"2022061702562644000_bib12","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1158\/0008-5472.CAN-10-2360","article-title":"HIF-1{alpha} confers aggressive malignant traits on human tumor cells independent of its canonical transcriptional function","volume":"71","author":"Yoo","year":"2011","journal-title":"Cancer Res"},{"key":"2022061702562644000_bib13","article-title":"The Universal Mutation Database: The VHL Mutations Database. Montpellier, France"},{"key":"2022061702562644000_bib14","doi-asserted-by":"crossref","first-page":"7582","DOI":"10.1158\/1078-0432.CCR-09-2131","article-title":"Analysis of VHL gene alterations and their relationship to clinical parameters in sporadic conventional renal cell carcinoma","volume":"15","author":"Young","year":"2009","journal-title":"Clin Cancer Res"},{"key":"2022061702562644000_bib15","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1002\/path.1034","article-title":"VHL mutations and their correlation with tumour cell proliferation, microvessel density, and patient prognosis in clear cell renal cell carcinoma","volume":"196","author":"Schraml","year":"2002","journal-title":"J Pathol"},{"key":"2022061702562644000_bib16","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/nrclinonc.2010.42","article-title":"Alterations in VHL as potential biomarkers in renal-cell carcinoma","volume":"7","author":"Gossage","year":"2010","journal-title":"Nat Rev Clin Oncol"},{"key":"2022061702562644000_bib17","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/humu.20385","article-title":"Genotype-phenotype correlations in von Hippel-Lindau disease","volume":"28","author":"Ong","year":"2007","journal-title":"Hum Mutat"},{"key":"2022061702562644000_bib18","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/prot.22419","article-title":"Structural bioinformatics mutation analysis reveals genotype-phenotype correlations in von Hippel-Lindau disease and suggests molecular mechanisms of tumorigenesis","volume":"77","author":"Forman","year":"2009","journal-title":"Proteins"},{"key":"2022061702562644000_bib19","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.juro.2008.05.015","article-title":"von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma","volume":"180","author":"Choueiri","year":"2008","journal-title":"J Urol"},{"key":"2022061702562644000_bib20","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/ncb899","article-title":"Regulation of microtubule stability by the von Hippel-Lindau tumour suppressor protein pVHL","volume":"5","author":"Hergovich","year":"2003","journal-title":"Nat Cell Biol"},{"key":"2022061702562644000_bib21","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1186\/1471-2407-9-229","article-title":"Differences in regulation of tight junctions and cell morphology between VHL mutations from disease subtypes","volume":"9","author":"Bangiyeva","year":"2009","journal-title":"BMC Cancer"},{"key":"2022061702562644000_bib22","doi-asserted-by":"crossref","first-page":"e3801","DOI":"10.1371\/journal.pone.0003801","article-title":"VHL type 2B mutations retain VBC complex form and function","volume":"3","author":"Hacker","year":"2008","journal-title":"PLoS One"},{"key":"2022061702562644000_bib23","article-title":"International classification of diseases (ICD). World Health Organization, Geneva, Switzerland"},{"key":"2022061702562644000_bib24","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1002\/path.1034","article-title":"VHL mutations and their correlation with tumor cell proliferation, microvessel density, and patient prognosis in clear cell renal cell carcinoma","volume":"196","author":"Schraml","year":"2002","journal-title":"J Pathol"},{"key":"2022061702562644000_bib25","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1158\/0008-5472.CAN-05-3074","article-title":"Genetic and epigenetic analysis of von Hippel-Lindau (VHL) gene alterations and relationship with clinical variables in sporadic renal cancer","volume":"66","author":"Banks","year":"2006","journal-title":"Cancer Res"},{"key":"2022061702562644000_bib26","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1038\/nature00767","article-title":"Structural basis for the recognition of hydroxyproline in HIF-1 alpha by pVHL","volume":"417","author":"Hon","year":"2002","journal-title":"Nature"},{"key":"2022061702562644000_bib27","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1126\/science.1073440","article-title":"Structure of an HIF-1alpha -pVHL complex: hydroxyproline recognition in signaling","volume":"296","author":"Min","year":"2002","journal-title":"Science"},{"key":"2022061702562644000_bib28","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1142\/S0219720007003120","article-title":"A structural bioinformatics approach to the analysis of nonsynonymous single nucleotide polymorphisms (nsSNPs) and their relation to disease","volume":"5","author":"Worth","year":"2007","journal-title":"J Bioinform Comput Biol"},{"key":"2022061702562644000_bib29","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1002\/prot.20252","article-title":"Sequence-based prediction of pathological mutations","volume":"57","author":"Ferrer-Costa","year":"2004","journal-title":"Proteins"},{"key":"2022061702562644000_bib30","article-title":"Site Directed Mutator: I-Mutant2.0. Thermodynamic database for protein and mutants. Crystallography and Bioinformatic Group, University of Cambridge, Cambridge, United Kingdom"},{"key":"2022061702562644000_bib31","article-title":"Site Directed Mutator: Mupro. Thermodynamic database for protein and mutants. Crystallography and Bioinformatic Group, University of Cambridge, Cambridge, United Kingdom"},{"key":"2022061702562644000_bib32","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1093\/protein\/10.1.7","article-title":"Prediction of the stability of protein mutants based on structural environment-dependent amino acid substitution and propensity tables","volume":"10","author":"Topham","year":"1997","journal-title":"Protein Eng"},{"key":"2022061702562644000_bib33","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1093\/bioinformatics\/btm073","article-title":"Andante: reducing side-chain rotamer search space during comparative modeling using environment-specific substitution probabilities","volume":"23","author":"Smith","year":"2007","journal-title":"Bioinformatics"},{"key":"2022061702562644000_bib34","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1016\/j.jmb.2004.08.022","article-title":"Distinguishing structural and functional restraints in evolution in order to identify interaction sites","volume":"342","author":"Chelliah","year":"2004","journal-title":"J Mol Biol"},{"key":"2022061702562644000_bib35","doi-asserted-by":"crossref","first-page":"pe30","DOI":"10.1126\/scisignal.124pe30","article-title":"pVHL: a multipurpose adaptor protein","volume":"1","author":"Frew","year":"2008","journal-title":"Sci Signal"},{"key":"2022061702562644000_bib36","doi-asserted-by":"crossref","first-page":"8817","DOI":"10.1073\/pnas.95.15.8817","article-title":"A second major native von Hippel-Lindau gene product, initiated from an internal translation start site, functions as a tumor suppressor","volume":"95","author":"Schoenfeld","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022061702562644000_bib37","doi-asserted-by":"crossref","first-page":"4726","DOI":"10.1158\/1078-0432.CCR-07-4921","article-title":"Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors","volume":"14","author":"Nickerson","year":"2008","journal-title":"Clin Cancer Res"},{"key":"2022061702562644000_bib38","doi-asserted-by":"crossref","first-page":"6660","DOI":"10.1158\/0008-5472.CAN-09-1133","article-title":"Cancer-specific high-throughput annotation of somatic mutations: computational prediction of driver missense mutations","volume":"69","author":"Carter","year":"2009","journal-title":"Cancer Res"},{"key":"2022061702562644000_bib39","doi-asserted-by":"crossref","first-page":"8507","DOI":"10.1073\/pnas.97.15.8507","article-title":"Elongin BC complex prevents degradation of von Hippel-Lindau tumor suppressor gene products","volume":"97","author":"Schoenfeld","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022061702562644000_bib40","doi-asserted-by":"crossref","first-page":"30388","DOI":"10.1074\/jbc.M203344200","article-title":"A molecular basis for stabilization of the von Hippel-Lindau (VHL) tumor suppressor protein by components of the VHL ubiquitin ligase","volume":"277","author":"Kamura","year":"2002","journal-title":"J Biol Chem"},{"key":"2022061702562644000_bib41","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1038\/nm1440","article-title":"E2-EPF UCP targets pVHL for degradation and associates with tumor growth and metastasis","volume":"12","author":"Jung","year":"2006","journal-title":"Nat Med"},{"key":"2022061702562644000_bib42","doi-asserted-by":"crossref","first-page":"8595","DOI":"10.1158\/0008-5472.CAN-04-1430","article-title":"In vitro and in vivo models analyzing von Hippel-Lindau disease-specific mutations","volume":"64","author":"Rathmell","year":"2004","journal-title":"Cancer Res"},{"key":"2022061702562644000_bib43","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1093\/hmg\/10.10.1029","article-title":"Contrasting effects on HIF-1alpha regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease","volume":"10","author":"Clifford","year":"2001","journal-title":"Hum Mol Genet"},{"key":"2022061702562644000_bib44","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1101\/gad.924501","article-title":"FIH-1: a novel protein that interacts with HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activity","volume":"15","author":"Mahon","year":"2001","journal-title":"Genes Dev"},{"key":"2022061702562644000_bib45","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.molcel.2008.12.004","article-title":"Small-molecule inhibitors of HIF-2a translation link its 5\u2032UTR iron-responsive element to oxygen sensing","volume":"32","author":"Zimmer","year":"2008","journal-title":"Mol Cell"},{"key":"2022061702562644000_bib46","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ccr.2007.07.006","article-title":"HIF and c-Myc: sibling rivals for control of cancer cell metabolism and proliferation","volume":"12","author":"Gordan","year":"2007","journal-title":"Cancer Cell"},{"key":"2022061702562644000_bib47","doi-asserted-by":"crossref","first-page":"3886","DOI":"10.2174\/138161209789649411","article-title":"HIF prolyl-4-hydroxylase interacting proteins: consequences for drug targeting","volume":"15","author":"Wenger","year":"2009","journal-title":"Curr Pharm Des"},{"key":"2022061702562644000_bib48","doi-asserted-by":"crossref","first-page":"38458","DOI":"10.1074\/jbc.M406026200","article-title":"Differential function of the prolyl hydroxylases PHD1, PHD2, and PHD3 in the regulation of hypoxia-inducible factor","volume":"279","author":"Appelhoff","year":"2004","journal-title":"J Biol Chem"},{"key":"2022061702562644000_bib49","doi-asserted-by":"crossref","first-page":"5729","DOI":"10.1128\/MCB.00331-09","article-title":"A feedback loop involving the Phd3 prolyl hydroxylase tunes the mammalian hypoxic response in vivo","volume":"29","author":"Minamishima","year":"2009","journal-title":"Mol Cell Biol"},{"key":"2022061702562644000_bib50","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1042\/BJ20041736","article-title":"Regulation of the prolyl hydroxylase domain protein 2 (phd2\/egln-1) gene: identification of a functional hypoxia-responsive element","volume":"387","author":"Metzen","year":"2005","journal-title":"Biochem J"},{"key":"2022061702562644000_bib51","doi-asserted-by":"crossref","first-page":"23482","DOI":"10.1074\/jbc.M601719200","article-title":"Increased prolyl 4-hydroxylase domain proteins compensate for decreased oxygen levels. Evidence for an autoregulatory oxygen-sensing system","volume":"281","author":"Stiehl","year":"2006","journal-title":"J Biol Chem"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/71\/16\/5500\/2653817\/5500.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/71\/16\/5500\/2653817\/5500.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T07:50:54Z","timestamp":1655452254000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/71\/16\/5500\/567715\/VHL-Gene-Mutations-and-Their-Effects-on-Hypoxia"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8,11]]},"references-count":51,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2011,8,11]]},"published-print":{"date-parts":[[2011,8,15]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-11-0757","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/0008-5472.22388070.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6502116","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22388070","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6502116.v1","asserted-by":"object"}]},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,8,11]]}}}